Loading…
Sonoma Pharmaceuticals, Inc. is projected to rise to $1.10 by 2027, a +2% move from its current price of $1.08. SNOA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.03 | $1.08 | $1.13 | -0.15% |
| May 30 | $1.01 | $1.08 | $1.15 | -0.30% |
| May 31 | $0.9901 | $1.08 | $1.17 | -0.45% |
| Jun 1 | $0.9761 | $1.07 | $1.18 | -0.60% |
| Jun 2 | $0.9638 | $1.07 | $1.19 | -0.75% |
| Jun 3 | $0.9526 | $1.07 | $1.20 | -0.90% |
| Jun 4 | $0.9424 | $1.07 | $1.21 | -1.05% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.9424 | $1.07 | $1.21 | -1.05% |
| Week 2 | $0.8852 | $1.06 | $1.26 | -2.08% |
| Week 3 | $0.8416 | $1.05 | $1.30 | -3.11% |
| Week 4 | $0.8052 | $1.04 | $1.33 | -4.12% |
| Week 5 | $0.7734 | $1.02 | $1.36 | -5.12% |
| Week 6 | $0.7451 | $1.01 | $1.38 | -6.11% |
| Week 7 | $0.7193 | $1.00 | $1.40 | -7.10% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Sonoma Pharmaceuticals, Inc. is a healthcare company focused on stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally.
Its product lineup includes Lumacyn, Regenacyn, Reliefacyn to alleviate red bumps, rashes, shallow skin fissures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for topical acne; Epicyn, Levicyn, Celacyn, Pediacyn, Microcyn, Ocucyn, Ocudox, Sinudox, Microdacyn60, Podiacyn, MicrocynAH, MicrocynVS, Nanocyn, Acuicyn, MucoClyns, and Endocyn, among others. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc.
in December 2016. Sonoma was incorporated in 1999 and is based in Boulder, Colorado.
SNOA is a healthcare stock trading at $1.10 per share with a market capitalization of $3.82M.
It is ranked 5401.
The long-term price path is outlined in the forecast, with a 2026 average of $1.10 and a 2050 average of $2.84, and a 2050 max of $6.53.
Forecasts show ROI increasing from 0% in 2026 to as high as 157.9% by 2050, with sentiment shifting toward BULLISH in later years.
A major floor 6.5% below — a decisive break under it would weaken the trend.
The nearest floor, 6.5% below — buyers have tended to step in here.
The nearest ceiling, 145.4% above — a clean break opens room to run.
A major ceiling 218.5% above — clearing it would confirm fresh momentum.
Key SNOA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SNOA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.07 | Buy | $1.08 | Buy |
| MA 10 | $1.08 | Sell | $1.10 | Sell |
| MA 20 | $1.13 | Sell | $1.22 | Sell |
| MA 50 | $1.75 | Sell | $1.67 | Sell |
| MA 100 | $2.41 | Sell | $2.20 | Sell |
| MA 200 | $3.18 | Sell | $2.73 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 35.22 | Neutral |
| Stoch RSI (14) | 99.77 | Sell |
| CCI (20) | -51.49 | Neutral |
| Williams %R (14) | -63.16 | Info |
| MACD (12,26,9) | 0.04 | Buy |
| ROC (12) | -10.00 | Sell |
| Bollinger %B (20,2) | 0.32 | Neutral |
| Stochastic %K (14) | 36.84 | Neutral |
| TRIX (15) | -2.19 | Sell |
| Awesome (5,34) | -0.41 | Sell |
| Ultimate (7,14,28) | 42.74 | Neutral |
| Momentum (10) | -0.10 | Sell |
| Aroon Osc (25) | -80.00 | Sell |
| Hull MA (9) | 1.08 | Buy |
| ADX (14) | 33.00 | Sell |
| ATR (14) | 0.06 | Info |
The 30-day technical picture shows a range from $0.7916 to $1.53.
RSI14 is 40, indicating NEUTRAL momentum. The price is below the SMA50 of $1.81 and well below the SMA200 of $3.20. Support sits at $1.01 and resistance at $2.65.
Annualized volatility is 100%, underscoring notable near-term risk and variability.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.01 | $1.08 | $1.29 | 0% | Neutral | |
| $0.8102 | $1.10 | $1.61 | +2% | Neutral | |
| $0.9199 | $1.32 | $2.04 | +22% | Bullish | |
| $0.9003 | $1.35 | $2.18 | +25% | Bullish | |
| $0.8687 | $1.35 | $2.27 | +25% | Bullish | |
| $0.7429 | $1.20 | $2.08 | +11% | Neutral | |
| $0.6847 | $1.15 | $2.04 | +6% | Neutral | |
| $0.721 | $1.25 | $2.28 | +16% | Neutral | |
| $0.8921 | $1.60 | $2.98 | +48% | Bullish | |
| $1.01 | $1.86 | $3.56 | +72% | Bullish | |
| $0.9687 | $2.08 | $4.35 | +93% | Bullish | |
| $1.27 | $2.82 | $6.50 | +162% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.01 | $1.08 | $1.27 | +0.00% |
| June 2026 | $0.8135 | $0.971 | $1.20 | -10.10% |
| July 2026 | $0.7773 | $0.9417 | $1.19 | -3.01% |
| August 2026 | $0.7812 | $0.9576 | $1.23 | +1.69% |
| September 2026 | $0.7281 | $0.9013 | $1.17 | -5.88% |
| October 2026 | $0.6876 | $0.8589 | $1.13 | -4.70% |
| November 2026 | $0.7311 | $0.9206 | $1.23 | +7.18% |
| December 2026 | $0.7568 | $0.9602 | $1.29 | +4.30% |
Click any year to see its month-by-month SNOA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Sonoma Pharmaceuticals, Inc.'s 2026 outlook centres on $1.08, within a $1.01 to $1.29 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, SNOA could reach as high as $1.61, with a base case around $1.10 and support toward $0.8102 — roughly +2% from $1.08. A consolidation phase looks the most probable path here.
Expect SNOA to range from $0.9199 to $2.04 through 2028. The $1.32 average target implies a +22% move from current prices. That is up +20% on the projected 2027 average. Momentum favours further upside here.
The SNOA price prediction for 2029 points to an average of $1.35 (low $0.9003, high $2.18) — a potential gain of +25% on today's $1.08. Buyers look set to stay in control over this stretch.
In 2030, SNOA is projected to trade between $0.8687 and $2.27, averaging $1.35 — a potential gain of +25% from today's $1.08. That is up 0% on the projected 2029 average. Momentum favours further upside here.
Sonoma Pharmaceuticals, Inc.'s 2031 outlook centres on $1.20, within a $0.7429 to $2.08 range. That is -11% versus the projected 2030 average. That marks a +11% change versus current levels. A consolidation phase looks the most probable path here.
By 2032, SNOA could reach as high as $2.04, with a base case around $1.15 and support toward $0.6847 — roughly +6% from $1.08. Price action looks broadly range-bound.
Expect SNOA to range from $0.721 to $2.28 through 2033. The $1.25 average target implies a +16% move from current prices. That is up +9% on the projected 2032 average. A consolidation phase looks the most probable path here.
The SNOA price prediction for 2034 points to an average of $1.60 (low $0.8921, high $2.98) — a potential gain of +48% on today's $1.08. Momentum favours further upside here.
In 2035, SNOA is projected to trade between $1.01 and $3.56, averaging $1.86 — a potential gain of +72% from today's $1.08. That is up +17% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Sonoma Pharmaceuticals, Inc.'s 2040 outlook centres on $2.08, within a $0.9687 to $4.35 range. That is up +12% on the projected 2035 average. That marks a +93% change versus current levels. Momentum favours further upside here.
By 2050, SNOA could reach as high as $6.50, with a base case around $2.82 and support toward $1.27 — roughly +162% from $1.08. Buyers look set to stay in control over this stretch.
Investing $1,000 in SNOA today (≈ 925.925926 SNOA) could be worth
$2,615.11
+$1,615.11 (+162%) by 2050 · US Dollar
Based on the average projected SNOA price of $2.82 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SNOAwould be worth at today's price.
$1,000 invested in SNOA on May 27, 2025 (≈ 314.465402 SNOA) would be worth
$339.62
-$660.38 (-66.0%) today · 0.34× · US Dollar
Based on a SNOA entry price of $3.18 vs. today's $1.08.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.07 | $1,009.35 | +0.9% |
| 1 month ago | $1.11 | $972.97 | -2.7% |
| 3 months ago | $2.93 | $368.6 | -63.1% |
| 6 months ago | $3.33 | $324.32 | -67.6% |
| 1 year ago | $3.18 | $339.62 | -66.0% |
| All time (5.0y) ago | $154.4 | $6.99 | -99.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SNOA forecast.
Our base-case forecast reaches $2.20 around 2050.
Implied market cap at $2.20: $7.64M
The multi-year forecast begins with NEUTRAL sentiment in 2026 (min $1.01, avg $1.10, max $1.31; ROI 0%) and remains NEUTRAL in 2027 (min $0.8123, avg $1.11, max $1.65; ROI 1.3%).
From 2028, the outlook shifts to BULLISH, with 2028 min $0.9414, avg $1.36, max $2.14 (ROI 24%), 2029 min $0.9033, avg $1.37, max $2.25 (ROI 24.7%), and 2030 min $0.8717, avg $1.38, max $2.36 (ROI 25.6%).
In the mid-2030s and beyond, sentiment remains BULLISH with stronger gains: 2034 min $0.9008, avg $1.66, max $3.16 (ROI 50.7%), 2035 min $0.9961, avg $1.90, max $3.70 (ROI 72.5%), 2040 min $0.9671, avg $2.15, max $4.58 (ROI 95.4%), and 2050 min $1.28, avg $2.84, max $6.53 (ROI 157.9%).
These figures are forecasts and not guarantees; actual results may vary and should be considered estimates.
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $1.38 with a min of $0.8717 and a max of $2.36, and a ROI of 25.6% with sentiment BULLISH.
The forecast includes a shift to BULLISH from 2028 onward, with higher expected average prices and ROIs reaching 157.9% by 2050, though early years remain NEUTRAL. Remember these are estimates, not guarantees.
Yes. The forecast max prices rise above $3 in several years: 2034 max $3.16 and 2035 max $3.70, with higher maxima of $4.58 in 2040 and $6.53 in 2050.
Current price is $1.10 and market capitalization is $3.82M.
The 30-day range is $0.7916 to $1.53. RSI14 is 40. SMA50 is $1.81 and SMA200 is $3.20. Support is $1.01 and resistance is $2.65.
Sonoma Pharmaceuticals, Inc. Community Discussion
0Share your Sonoma Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.